Your session is about to expire
← Back to Search
Other
The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression
N/A
Waitlist Available
Research Sponsored by University of the Incarnate Word
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this test will occur prior to the intervention (meibomian gland expression) and immediately after this intervention.
Awards & highlights
No Placebo-Only Group
Summary
This trial explores how MGD dry eye affects sight & how non-invasive MG expression can improve vision.
Eligible Conditions
- Meibomian Gland Dysfunction
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ this test will occur prior to the intervention (meibomian gland expression) and immediately after this intervention.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this test will occur prior to the intervention (meibomian gland expression) and immediately after this intervention.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Cone Contrast Sensitivity on the Cone Contrast Test (CCT, Innova Systems, Inc.)
Change in Response Time on Cone Contrast Test (CCT, Innova Systems, Inc.)
Secondary study objectives
Change in Black White Contrast Sensitivity (Innova Systems, Inc)
Change in Color Naming Accuracy on Cone Contrast Color Naming test (CCNT)
Change in Response Time on Black White Contrast Sensitivity Test (Innova Systems, Inc) Response Time
+3 moreOther study objectives
Change in High Contrast Visual Acuity
Change in Small Letter Contrast Sensitivity
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: non-invasive Meibomian gland (MG) expressionExperimental Treatment1 Intervention
Baseline testing of visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured.
The intervention will be standard clinical expression of Meibomian superior and inferior glands (MG) using a sterile cotton tip applicator to apply gentle pressure in a rolling motion in the direction of the MGs along the upper and lower eyelid margins to allow oil secretion of the tested eye. One drop of sterile saline will be instilled following the intervention to remove debris. The subject's visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured before and after this intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Meibomian gland (MG) expression
2023
N/A
~40
Find a Location
Who is running the clinical trial?
University of the Incarnate WordLead Sponsor
17 Previous Clinical Trials
2,445 Total Patients Enrolled
4 Trials studying Meibomian Gland Dysfunction
131 Patients Enrolled for Meibomian Gland Dysfunction
Jeffery Rabin, OD, PhDStudy ChairUniversity of the Incarnate Word